Clotting Factors

U.S. FDA expands approval of Roche hemophilia drug

Analysts, Bleeding, Clotting Factors, Factor Replacement Therapies, FDA/Regulatory, Genetic Disorders, Hemophilia A, Hemophilia B, Patent Protection, Potential Blockbusters

U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.

October 4, 2018/by Reuters Health

With Hemlibra, Roche seeks to break into tight hemophilia circle

Bleeding, Business, Chromosomes, Clotting Factors, FDA, Forecasts, Gene Therapy, Genetic Disorders, Hemophilia A, Therapeutics, X Chromosome

Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.

October 3, 2018/by Reuters Health